Booth: 501, 618
AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.
Accredo is a full-service specialty pharmacy dedicated to the treatment of rare and complex conditions. Our comprehensive therapy management programs engage specialty-trained pharmacists, nurses, reimbursement specialists, and patient care representatives who provide enhanced support services to patients, their families, and healthcare professionals.
A non-profit scientific association founded in 1968, whose main objective is to promote and disseminate the study of Hepatology in Latin America, through training and the exchange of scientific knowledge and experiences, to reduce current gaps in the world.
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders, including lysosomal acid lipase deficiency (LAL-D). Learn more at www.alexion.com.
Allergan plc (NYSE: AGN), is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. For more information, visit Allergan's website at www.Allergan.com.
The American Board of Internal Medicine (ABIM) has stood for the highest standard in internal medicine and its 20 subspecialties. Certification has meant that internists have demonstrated – to their peers and to the public – that they have the clinical judgment, skills and attitudes essential for the delivery of excellent patient care. ABIM is not a membership society, but a physician-led non-profit, independent evaluation organization.
Founded in 1976, the American Liver Foundation (ALF) is the nation's leading nonprofit health organization for people living with liver disease. We are a nationwide network of staff and volunteers that provides awareness, outreach, education and patient support services to educate the public about liver health and to improve the lives of individuals and their families affected by liver disease.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power.
Bionutrigen is making strong effort to make the world top level liver health food which is useful for a liver health and alcohol detoxification without any side effect. We are a proven company that passed through European and Russian clinical trials. Our products are exported to Russia, China and U.S.A.
BioPredictive offers diagnostic and prognostic blood tests for liver diseases. Over a million tests performed worldwide. BioPredictive's diagnosis and prognosis tests (FiboTest-ActiTest, FibroMax, HCV-GenoFibroTest including IL28b ) are available on line at www.biopredictive.com FibroTest App (free) including ElastoFibroTest and DAAFibroTest available on iPhone and Android.
Boston Scientific is dedicated to transforming patient lives by developing diagnostic and therapeutic devices that support less invasive, more efficient procedures for a variety of GI conditions. Through innovation and partnership, we are advancing important clinical research, supporting education programs and helping healthcare institutions deliver high quality healthcare while managing costs.
BriovaRx is a leading specialty pharmacy services company dedicated to helping administer and deliver high-quality, cost-effective specialty pharmacy care.BriovaRx combines technology, data and expertise to provide educational resources, 24/7 pharmacy support and trusted advice to the individuals, caregivers and care teams we serve.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Visit BMS at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.
Founded in 2006, the Cholangiocarcinoma Foundation is a global 501(c) (3) non-profit organization whose mission is to find a cure and improve the quality of life for those affected by bile duct cancer.
The CHBG is a non-profit, international clinical research group. In issue 7, 2016 of The Cochrane Library, we published 303 peer-reviewed protocols and 181 systematic reviews. A CHBG Register on randomised and controlled clinical trials is maintained in the CENTRAL database. Cochrane reviews are not industry funded.
We build bridges connecting patients to health care providers and services; create and conduct educational workshops and seminars; coordinate support groups; work with local media and community groups to increase awareness of liver wellness and liver disease; and meet with local, state, and federal policy makers to initiate positive change.
CTI is a global, privately held, full-service CRO with a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. We specialize in the unique challenges associated with hepatic populations, and our therapeutic expertise is a driving force enabling us to successfully design/manage drug development programs in hepatology.
Our commitment to helping patients and their physicians manage complex drug therapies by delivering expert individualized care and unmatched, multi-channel access has made us one of the leading specialty pharmacies in the country. We provide a full-range of pharmaceutical care, dispensing the latest FDA-approved medications.
See what's new in CK18 biomarkers for NASH and AH research at Booth 543. CK18 plays a role in cell death. Explore M30/M65 ELISAs for measuring hepatocyte apoptosis and cell death non-invasively. Diapharma offers an extensive line of liver injury biomarkers, including K18, HA, α-GST, and Collagen IV. Research use only.
Discover monumental developments in science and medicine at Digestive Disease Week(r) (DDW) 2018. DDW is the premier event for gastroenterology, hepatology, endoscopy and gastrointestinal surgery professionals. Visit us to learn about liver programming and enter our raffle for a fun prize. Join us June 2–5, 2018, in Washington DC.
The Duke Clinical Research Institute (DCRI), the largest academic research organization globally, conducts groundbreaking multinational clinical trials, manages major national patient registries, and performs landmark outcomes research. The DCRI combines the faculty expertise of one of the most prestigious university medical centers with full-service operational capabilities.
Echosens is the world's leading provider of non-invasive, point of care medical devices dedicated to the liver. Our FibroScan(r) devices are the first to be FDA cleared as an aid for managing patients with liver disease. Echosens also offers the FibroView(tm) connectivity solution as well as the FibroMeter(tm) blood test.
Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity.
At EntrustRx, we provide all specialty pharmacy needs from patient assistance with copays to nurse training. We believe in a high touch model of care and dedicate ourselves to helping patients every step of the way. At EntrustRx, we are confident we provide the best service possible in specialty pharmacy.
Since 1966, EASL has continued to grow into a major European Association with international influence dedicated to liver research. It has over 4,000 members and its International Liver Congress(tm) unites over 10,000 liver experts. EASL supports clinical trials and research to the benefit of patients world-wide.
ExeGi Pharma distributes Visbiome, a high potency probiotic medical food intended for the dietary management of dysbiosis associated with irritable bowel syndrome, ulcerative colitis, pouchitis and hepatic encephalopathy. Visbiome offers a very high potency of bacteria ranging from 112.5 billion bacteria per CFU-900 billion bacteria per CFU, depending on the product. Visbiome is available in capsules, packets, and prescription-strength packets.
Gastroenterology & Endoscopy News, a monthly newspaper, provides smart, objective and comprehensive clinical news reporting from international, national and regional gastroenterology meetings. It also features in-depth original articles, educational reviews, CME monographs and monthly commentary from celebrated gastroenterologists.
Gastroenterology & Hepatology is a monthly, independent peer-reviewed journal that is mailed to all US gastroenterologists and hepatologists (16,700+). Content is directed by strong input of experts in the field. G&H contains thought leader-driven review articles, clinical case studies with expert commentary, and advances columns featuring engaging interviews with experts on current issues in IBD, IBS, GERD, Hepatitis and Endoscopy.
GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. Elafibranor, its lead compound, is currently evaluated in a large pivotal international Phase 3 study.
Booth: 317, 320, 327
Gilead Sciences, Inc., founded in 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead's portfolio includes treatments for HIV/AIDS, hepatitis, respiratory and cardiovascular conditions, cancer and inflammation. Gilead is one of the world's largest biopharmaceutical companies, with approximately 5,500 employees across four continents.
The Gore Medical Products Division has provided creative solutions to medical problems for four decades. Over 40 million Gore Medical Devices have been implanted worldwide. Products include vascular grafts, endovascular and interventional devices, surgical materials, and sutures for use in vascular, cardiac and general surgery. For more information, visit www.goremedical.com.
Grifols is a global healthcare company whose mission is to improve the health and well-being of people around the world. We have three primary divisions – Bioscience, Diagnostic and Hospital – that develop, produce and market our innovative products and services to medical professionals in more than 100 countries around the world.
The HealthWell Foundation is an independent nonprofit dedicated to reducing financial barriers to care for underinsured Americans with chronic and life-altering medical conditions. HealthWell offers a financial lifeline to adults and children who desperately need critical medical treatments but can't afford them by assisting with their cost-sharing obligations. Learn more: www.HealthWellFoundation.org.
HepVu.org is an interactive online resource that visualizes the first standardized state-level estimates of people with past or current Hepatitis C infection across the U.S. These estimates were generated by Emory University's Coalition for Applied Modeling for Prevention (CAMP), a project supported by the Centers for Disease Control and Prevention (CDC).
Hong Kong Humanity & Health Medical Group, composed with H&H Research Center; H&H Medical Center (GI & Liver Center, Digestive Endoscopy Centre, Hepatitis C Diagnosis & Treatment Center cooperated with Beijing 302 Hospital of PLA); Explicit Global Medical Group Limited (Medical Diagnostic and Health Assessment Center, Medical Laboratory Center). Visit us at www.hnhmgl.com
Booth: 242, 533
Intercept is a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat underserved chronic liver diseases such as primary biliary cirrhosis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. Our product candidates have the potential to treat liver diseases for which there currently are limited therapeutic options.
LabCorp is one of the nation's premier laboratories for treating infectious disease, including Hepatitis C Virus. Through an extensive test menu, staff expertise, and integrated testing from our Center's of Excellence (Monogram BioSciences, The Center for Molecular Biology and Pathology and ViroMed Laboratories), LabCorp offers a single-source solution for the treatment of acute and chronic infections.
Median is at the heart of innovative imaging solutions with iBiopsy(r), a platform designed to acquire, index, and analyze thousands of phenotypes, decoding the biomarkers from standard medical images, to help predict a patient's response to treatment. iBiopsy(r) will revolutionize the way we diagnose, treat and monitor patients with NASH.
Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. For more information visit www.merck.com.
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) exhibit highlights the importance of alcohol research, prevention, and treatment for maintaining health. The NIAAA booth features publications appropriate for the public, research findings for professionals and policy makers, and research grant opportunities available for biomedical and social science researchers.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis products are available in more than 180 countries around the world. www.novartis.com
OWL, a global leader in liquid biopsy testing for NASH and related diseases, will be presenting new data related to innovations in NASH, NAFLD, subtyping of NAFLD severity and fiber staging, via blood-based, non-invasive metabolomics assays. OWL will host various activities in Washington, including a booth and scientific abstracts
OraSure Technologies manufactures oral fluid devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for HIV and HCV antibodies, influenza antigens, testing solutions for detecting drugs of abuse, and oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.
Organovo develops dynamic, multicellular, 3D bioprinted human tissues that closely mimic native architecture and function for the advancement of preclinical safety testing, disease modeling, ADME, and therapeutic applications. Available through its NovoView(tm) Preclinical Services, ExVive(tm) 3D Bioprinted Liver and Kidney Tissues model human biology for effective translation to the clinic.
Our mission is to unite people diagnosed with Primary Biliary Cholangitis (formerly known as Primary Biliary Cirrhosis), which is a progressive chronic liver disease. Our organization helps PBC patients, their care givers, friends and families cope with PBC and improve the quality of their lives through education and support.
Perspectum Diagnostics' proprietary technology and flagship product, LiverMultiScan, is a customisable software analysis tool that uses innovative multiparametric MRI for whole liver assessment. It quickly and accurately measures liver fat as well as correlates for iron and fibrosis/inflammation. Perspectum's research platform, LiverMultiScan Discover, is currently supporting research and clinical trials.
Philips is a leading health technology company focused on improving people's health and enabling better outcomes. Philips EPIQ ultrasound system features the Ultimate Ultrasound Liver solution to non-invasively assess liver disease, including ElastQ Imaging, a real-time, large Region of Interest (ROI), color-coded quantitative assessment of tissue stiffness using shear wave elastography.
PhoenixBio produces the PXB-Mouse(r), the world's most widely used humanized liver chimeric mouse model, for pre-clinical development. With a liver consisting of up to 95% human hepatocytes, the PXB-Mouse(r) offers excellent human translatability in the fields of DMPK/Tox, HBV/HCV, NASH/NAFLD and Gene Editing/Oligonucleotide Therapeutics, leading to earlier clinical studies.
Plexision develops and markets cell-based tests for personalized disease management and drug development for the Immunocompromized host. The company's first product, Pleximmune, is FDA-approved to predict rejection in children with liver or intestine transplantation. Plexision's products and services are offered from its CLIA-approved, GLP- and GMP-compliant reference laboratory.
PSC Partners Seeking a Cure provides education and support to PSC patients, families and caregivers, and raises funds to research causes, treatments and cures for Primary Sclerosing Cholangitis. PSC Partners has awarded $2 million in research grants, has a growing patient registry, and holds annual conferences for patients and caregivers.
Recordati Rare Diseases is a biopharmaceutical company committed to providing urgently needed therapies to people with rare diseases in the U.S. We strive to reduce the impact of these diseases and restore health. Our team works with rare disease communities to increase awareness, improve diagnosis, and ensure access to effective treatments.
Resoundant Inc. is the supplier of Magnetic Resonance Elastography (MRE), an advanced imaging technology for measuring tissue stiffness and aiding diagnosis and staging of liver fibrosis. Developed at the Mayo Clinic, MRE can provide physicians with a comprehensive assessment of liver health. Follow us on Twitter @Resoundant during The Liver Meeting. Visit us at Booth #111.
Retrophin is a biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options.
For over 20 years, Salix Pharmaceuticals, a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. has been committed to providing solutions for the management of many chronic and debilitating conditions. Salix currently markets products to U.S. healthcare providers in the areas of gastroenterology, hepatology, internal medicine, primary care, infectious disease, and allergy/immunology.
Samsara Sciences, Inc. specializes in the provision of primary human liver cells for use in human biology and disease research. Our products include hepatocytes, stellate cells, endothelial cells, and Kupffer cells, isolated from healthy or diseased donors with confirmed NAFLD or fibrosis. In addition to cryopreserved cells, we offer tissue-of-origin paraffin blocks and snap-frozen tissues.
Sanyal Biotechnology is a contract research organization specializing in pre-clinical small animal model screening of drugs. We have developed a proprietary mouse model, the DIAMONDTM mouse, that develops NAFLD and NASH solely as a result of Western Diet.
We're reporting LIVE. Follow what's trending at Healio.com/GI. See what your peers are reading online – in print. Stop by our booth and pick up your free issue of Healio Gastroenterology – a unique peer-tested news magazine. Also see HCV Next. Go to Healio.com/Register.
SuperSonic Imagine is an innovative ultrasound imaging company that has developed a revolutionary ultrasound system: the Aixplorer(r). Aixplorer is the only system on the market with a real time ShearWave(tm) Elastography exam. The exam takes as little as 60 seconds and provides image guided quantification of liver tissue stiffness.
The leading providers of innovative programs for scientific interchange, knowledge-sharing and education for the healthcare professional. Virology Education is committed to delivering highly acclaimed and accredited meetings annually for healthcare professionals worldwide.
Vital Therapies, Inc. is a biotherapeutic company developing a human hepatic cell-based system for the treatment of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver treatment currently in Phase 3 clinical trials for acute alcoholic hepatitis.
Wako Diagnostics offers biomarkers AFP-L3 (lectin-reactive alpha-fetoprotein) and DCP (des-gamma-carboxy prothrombin) to aid in the early detection of hepatocellular carcinoma (HCC) in at-risk patients, increasing the possibility of timely application of curative therapies and improved patient outcomes. Both blood tests are 510(k)-cleared, CMS reimbursed, and available at major reference laboratories.
Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments, and individuals increase the academic and professional impact of their work.
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics' lead product, WTX101, is initially being developed as a novel treatment for Wilson Disease and has been evaluated in a Phase 2 clinical study.
The World Gastroenterology Organisation (WGO) is a federation comprised of over 100 member societies representing more than 50,000 individuals worldwide. WGO focuses on the improvement of standards in gastroenterology training and education globally. The WGO Foundation is the philanthropic resource for the WGO mission.